Liquid Biopsy Predicts Immunotherapy Response, Toxicity in Advanced Lung Cancer Patients
Liquid biopsies could predict which lung cancer patients are responding to immunotherapies or may develop immune-related side effects.
Read MorePosted by Andy Lundin | Dec 12, 2023 | Lung Cancer |
Liquid biopsies could predict which lung cancer patients are responding to immunotherapies or may develop immune-related side effects.
Read MorePosted by Andy Lundin | Dec 11, 2023 | Cancer, Digital Pathology |
Researchers at UT Southwestern Medical Center developed a novel AI model that analyzes the spatial arrangement of cells in tissue samples.
Read MorePosted by Andy Lundin | Dec 8, 2023 | Breast |
Exai Bio’s liquid biopsy platform can detect breast cancer at the earliest stages and the smallest tumor sizes using a standard blood sample.
Read MorePosted by Andy Lundin | Dec 5, 2023 | Cancer |
UCLA Researchers received $9.1 million in grant funding from the National Cancer Institute to advance liquid biopsy tech for cancer detection.
Read MorePosted by Andy Lundin | Dec 4, 2023 | Cancer, Company News |
Personalis and Tempus Labs announced a collaboration to co-commercialize a whole genome-based liquid biopsy LDT for MRD and cancer detection.
Read More